Clinical Trial Update: Study Comparing the Safety and Efficacy of Two Doses of BC-3781 vs Vancomycin in Patients With Acute Bacterial Skin and Skin Structure Infection (ABSSSI) [Phase 2]

View source ↗

Summary

Phase 2 trial comparing two doses of BC-3781 with vancomycin for acute bacterial skin and skin structure infection (ABSSSI) has completed with results posted.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Bacterial Skin and Skin Structure Infection

Drugs mentioned

• BC-3781
• Vancomycin (vancomycin)

Snippet

Sponsor: Nabriva Therapeutics AG | Conditions: Bacterial Infections, Infection | Phase 2 | Status: COMPLETED | Results posted: 2020-10-27